Jon Weiss
Head, Business Development Cellenkos
Dr. Jon Weiss brings over 20 years of biotechnology and research experience, spanning scientific, business development, and executive roles. He has served as Director of Business Development and CEO of Stellate Therapeutics, on Regeneron’s Genetic Medicines BD team, and as Principal Scientist at Kadmon Pharmaceuticals. During his PhD, he studied Treg cells and later helped develop Rezurock (belumosudil), the only FDA-approved Treg-attenuating therapy. Dr. Weiss also offers deep expertise in licensing, M&A, and strategic planning within genetic medicines, making him a key asset to Cellenkos as it advances innovative Treg-based therapeutics to patients.
Seminars
Wednesday 25th March 2026
Industry Leader’s Fireside Chat: Evaluating the Global Treg Landscape to Explore the Future of Space
8:40 am
- Exploring the global Treg landscape to identify emerging opportunities and the direction of future Treg development
- Exploring the interest in Treg collaboration and investment amid industry changes and recent changes in the industry
- Discussing the broad landscape of Treg therapy economics considering cost, reimbursement and tariff impacts
